For twenty years, the story western pharma told about China was simple. China made things. The molecules, the science, the intellectual property, all of that stayed in Boston, Basel and Cambridge. China was where you scaled, not where you discovered.
That story is now wrong, and the numbers say so plainly. In 2025, roughly a third of the value of global pharma licensing deals came from assets that originated in China. That is not a rounding error. It is a structural shift in where new medicine is being invented.
The question is no longer whether to look at China. It is whether your competitors are looking first.
Look at the flow of deals. Large western companies are increasingly in-licensing early-stage and clinical assets from Chinese biotechs, in oncology, in metabolic disease, in immunology. The Chinese firms have gotten faster and cheaper at the part of drug development that used to be the west's edge: moving a candidate from bench to early clinical proof. Speed compounds. A company that runs its early trials in eight months instead of eighteen gets more shots on goal per year.
What this means for a pipeline strategy
If you lead R&D, business development or strategy at a health or pharma company, three things follow.
First, sourcing. A serious pipeline review in 2026 has to include Chinese-origin assets, or it is not serious. The best early-stage science is no longer concentrated in the places you already visit.
Second, relationships. Deals happen between people who have met. The firms winning the good assets are the ones whose leaders have sat in the labs in Shanghai and Suzhou, understood the team, and built trust before the auction starts. You cannot do that from a data room.
Third, speed of judgement. The advantage goes to the buyer who can assess an asset and a team quickly and with conviction. That conviction comes from having seen enough of the ecosystem to know good from noise.
Where we come in
This is the gap Xcubed exists to close. We take health and pharma leaders into the Chinese innovation ecosystem, into the specific labs and companies that matter for their pipeline, and we frame the visit before and translate it after. The immersion is the method. The decision is the point.
The map has changed. The leaders who redraw theirs first will be licensing the medicines everyone else reads about in two years.